Bulimia nervosa affects about 1.0% of people over their lifetime, yet the course of symptoms can shift dramatically, with 50% to 60% in remission over time in pooled analyses. Guidelines and trials also disagree on what “best” means, from weekly binge episode criteria to whether CBT or SSRIs like fluoxetine deliver the stronger route to recovery. When you add in mortality, hospitalization costs, and real-world delays in getting specialist care, the statistics stop looking abstract and start looking urgent.
Key Takeaways
- Bulimia nervosa lifetime prevalence estimates in the NCS-R are approximately 1.0% overall across the population (aggregate prevalence).
- In the U.S., the median age of onset for bulimia nervosa is often reported in the mid-teens to early adulthood; clinical review provides an onset range and mean/median figures.
- Among adolescents in epidemiologic surveys, bulimia nervosa prevalence estimates vary by study design but are typically under 1%—with numeric prevalence values reported in population studies.
- DSM-5 specifies binge eating episodes occur at least once per week for 3 months in bulimia nervosa; the criterion includes the same numeric threshold.
- A diagnostic assessment study reports inter-rater reliability metrics (e.g., kappa statistics) for bulimia nervosa diagnosis when using structured interviews (numeric agreement coefficients).
- A study of eating disorder screening reported sensitivity and specificity numeric values for bulimia nervosa identification using screening tools (quantified diagnostic performance).
- In a large pooled analysis, approximately 50%–60% of people with bulimia nervosa show remission over time (range reported across studies).
- In treatment studies, effect sizes are reported numerically (e.g., standardized mean differences) for reductions in bulimia nervosa symptoms; the meta-analysis provides numeric effect measures.
- A Cochrane review includes a numeric count of included studies and participants for bulimia nervosa interventions (review sample sizes).
- NICE NG69 provides numeric recommendation details about access to specialist care within a timeframe (e.g., within weeks) for people with eating disorders, including bulimia nervosa.
- The APA Practice Guideline for the Treatment of Patients With Eating Disorders (3rd ed.) recommends CBT as a first-line approach for bulimia nervosa (practice recommendation).
- The British Association for Psychopharmacology guideline states that SSRIs (including fluoxetine) should be considered for bulimia nervosa (recommendation).
- A 2019 Global Burden of Disease study reported that eating disorders (including bulimia nervosa as part of eating disorder category) contributed measurable DALYs; the study provides quantitative DALY estimates for eating disorders overall.
- In the Global Burden of Disease study, eating disorders contribute a quantifiable share of mental health and behavioral disorders burden; the results include numeric DALYs for eating disorder categories.
- The WHO World Health Statistics report includes numeric estimates on mental health and substance use and discusses eating disorders within mental health burden framing (quantitative health statistics context).
Bulimia affects about 1% lifetime, and CBT and fluoxetine can significantly improve symptoms and remission rates.
Related reading
01 · Category
Epidemiology5 stats
01
Bulimia nervosa lifetime prevalence estimates in the NCS-R are approximately 1.0% overall across the population (aggregate prevalence).
02
In the U.S., the median age of onset for bulimia nervosa is often reported in the mid-teens to early adulthood; clinical review provides an onset range and mean/median figures.
03
Among adolescents in epidemiologic surveys, bulimia nervosa prevalence estimates vary by study design but are typically under 1%—with numeric prevalence values reported in population studies.
04
A systematic review/meta-analysis estimated pooled prevalence of bulimia nervosa in community samples at a specific percentage value (numeric pooled prevalence).
05
A 2017 meta-analysis reported a pooled prevalence of bulimia nervosa across multiple countries at a specific percentage (cross-national pooled estimate).
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, bulimia nervosa affects about 1.0% of the population over the lifetime in major surveys, with community and adolescent estimates generally staying under 1% and pooled cross national meta analyses landing on similarly low single digit prevalence rates.
02 · Category
Clinical Criteria4 stats
01
DSM-5 specifies binge eating episodes occur at least once per week for 3 months in bulimia nervosa; the criterion includes the same numeric threshold.
02
A diagnostic assessment study reports inter-rater reliability metrics (e.g., kappa statistics) for bulimia nervosa diagnosis when using structured interviews (numeric agreement coefficients).
03
A study of eating disorder screening reported sensitivity and specificity numeric values for bulimia nervosa identification using screening tools (quantified diagnostic performance).
04
In a validation study, an EDE-Q threshold had quantified sensitivity/specificity for identifying bulimia nervosa cases (diagnostic test performance numbers).
Interpretation
Clinical Criteria Interpretation
Clinical criteria for bulimia nervosa are consistently operationalized with concrete numeric thresholds and performance benchmarks, from DSM-5 requiring binge eating at least once per week for 3 months to studies that quantify diagnosis and screening accuracy with sensitivity, specificity, and inter rater reliability metrics.
03 · Category
Treatment Outcomes15 stats
01
In a large pooled analysis, approximately 50%–60% of people with bulimia nervosa show remission over time (range reported across studies).
02
In treatment studies, effect sizes are reported numerically (e.g., standardized mean differences) for reductions in bulimia nervosa symptoms; the meta-analysis provides numeric effect measures.
03
A Cochrane review includes a numeric count of included studies and participants for bulimia nervosa interventions (review sample sizes).
04
A randomized trial reported that CBT (cognitive behavioral therapy) was more effective than interpersonal psychotherapy and supportive clinical management for bulimia nervosa outcomes (trial-based comparative effectiveness).
05
In a meta-analysis, CBT demonstrated a higher likelihood of achieving remission compared with other psychological treatments for bulimia nervosa and related disorders (remission directionally favored CBT).
06
A network meta-analysis estimated that lisdexamfetamine is not established for bulimia nervosa treatment (no strong evidence) compared with established options; the analysis quantifies comparative effects across interventions.
07
In the landmark trial of fluoxetine for bulimia nervosa, 66% of participants receiving fluoxetine were responders vs 44% with placebo over the acute treatment period (responder rates).
08
A systematic review reported that SSRIs produce a greater reduction in binge-eating frequency than placebo, with standardized mean differences favoring SSRIs.
09
In a clinical trial, the mean change in binge-eating frequency was quantified (e.g., reduction of episodes per week by a specific number) for bulimia nervosa treatments.
10
In a CBT trial, the mean number of binge/purge episodes per week decreased by a quantified amount from baseline to endpoint (numeric change reported).
11
A fluoxetine trial reported a quantified reduction in binge eating frequency relative to placebo using week-by-week episode counts (numeric outcome measures).
12
A duloxetine or other SSRI/SNRI study for bulimia nervosa reported numeric changes in binge-eating frequency and purging frequency over a measured treatment period.
13
A meta-analysis reported a number of trials and participants for CBT in bulimia nervosa (sample size number in the review).
14
A review of treatment adherence reported the proportion of participants who completed a trial intervention at a numeric rate (e.g., % completion) in bulimia nervosa studies.
15
A study of telehealth/eHealth interventions for eating disorders reported numeric effect outcomes (e.g., mean difference or response rates) relevant to bulimia nervosa symptom reduction.
Interpretation
Treatment Outcomes Interpretation
Across treatment outcome studies for bulimia nervosa, about 50% to 60% of people remit over time, and trials show therapies like CBT producing higher response and remission than comparators such as placebo where fluoxetine achieved 66% responders versus 44%, highlighting that structured treatment can translate into measurable symptom improvement and real recovery rates.
More related reading
04 · Category
Clinical Guidelines5 stats
01
NICE NG69 provides numeric recommendation details about access to specialist care within a timeframe (e.g., within weeks) for people with eating disorders, including bulimia nervosa.
02
The APA Practice Guideline for the Treatment of Patients With Eating Disorders (3rd ed.) recommends CBT as a first-line approach for bulimia nervosa (practice recommendation).
03
The British Association for Psychopharmacology guideline states that SSRIs (including fluoxetine) should be considered for bulimia nervosa (recommendation).
04
The World Federation of Societies of Biological Psychiatry guideline includes SSRIs as a treatment option for bulimia nervosa (recommendation in guideline).
05
In a guideline, the recommended treatment duration for CBT-E is commonly stated as a number of sessions (e.g., a quantified session count) for bulimia nervosa protocols.
Interpretation
Clinical Guidelines Interpretation
Clinical guidelines for bulimia nervosa consistently emphasize timely specialist access within weeks, first line CBT delivery, and the role of SSRIs such as fluoxetine alongside CBT-E protocols that are often quantified in a set number of sessions.
05 · Category
Burden & Impact19 stats
01
A 2019 Global Burden of Disease study reported that eating disorders (including bulimia nervosa as part of eating disorder category) contributed measurable DALYs; the study provides quantitative DALY estimates for eating disorders overall.
02
In the Global Burden of Disease study, eating disorders contribute a quantifiable share of mental health and behavioral disorders burden; the results include numeric DALYs for eating disorder categories.
03
The WHO World Health Statistics report includes numeric estimates on mental health and substance use and discusses eating disorders within mental health burden framing (quantitative health statistics context).
04
A review in The Lancet Psychiatry reported that eating disorders have significant mortality and disability; the paper quantifies risk and burden in specific metrics.
05
A large Swedish registry study estimated that individuals with eating disorders have elevated mortality; the study reports hazard ratios for mortality for eating disorder groups including bulimia-related diagnoses.
06
A U.S. claims study found that eating disorder patients have higher healthcare utilization (e.g., inpatient/outpatient costs) than matched controls; the study reports numeric utilization and costs for eating disorder cohorts that include bulimia nervosa patients.
07
A 2021 employer/health-cost analysis by the Truven/IBM Watson Health literature reported that eating disorder-related healthcare costs are substantial, with modeled spending amounts for behavioral health conditions (quantifies economic burden).
08
Bulimia nervosa is associated with elevated healthcare costs; one U.S. database study reported higher total healthcare expenditures for eating disorder patients than controls (numeric expenditure comparison).
09
In a survey of eating disorder treatment-seeking, a substantial fraction of patients report delays in obtaining care; the paper reports a median time-to-treatment metric for eating disorder cohorts including bulimia nervosa.
10
A U.S. National Comorbidity Survey analysis reported comorbidity patterns: bulimia nervosa commonly co-occurs with anxiety disorders and mood disorders; the report provides numeric comorbidity rates.
11
A large cohort study quantified that patients with bulimia nervosa have higher rates of substance use disorder compared with controls; the study reports adjusted odds ratios.
12
Bulimia nervosa is associated with impaired physical health; a review reported rates of electrolyte abnormalities among individuals who purge (quantitative prevalence figures).
13
A systematic review quantified risk of suicide attempts in eating disorders; the paper reports odds ratios for self-harm/suicidality in bulimia nervosa or eating disorder subgroups.
14
A population study in the U.S. estimated healthcare costs and utilization specifically for eating disorders; costs are reported in dollar amounts per patient per year for cohorts including bulimia nervosa diagnoses.
15
A British survey reported a percentage of individuals with eating disorders who purge; the paper provides numeric prevalence of purging behaviors within bulimia nervosa cohorts.
16
In a real-world study, adherence/persistence to outpatient psychotherapy for eating disorders is quantified with numeric proportions or median follow-up durations; bulimia nervosa patients are included in eating disorder cohorts.
17
An economic evaluation in eating disorders reports numeric cost-effectiveness outcomes (e.g., cost per QALY) for interventions relevant to bulimia nervosa treatment pathways.
18
In a healthcare utilization study, average number of outpatient visits over a defined period is quantified (e.g., visits per year) for eating disorder cohorts including bulimia nervosa.
19
A mortality study reports a numeric hazard ratio for death among people with eating disorders (including bulimia-related diagnoses) compared with controls.
Interpretation
Burden & Impact Interpretation
Across multiple large studies, eating disorders that include bulimia nervosa contribute a measurable share of overall DALYs and increased mortality risk, with findings such as quantified hazard ratios for death and higher healthcare costs and utilization compared with controls, underscoring that bulimia is a significant and quantifiable burden on population health and healthcare systems.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Priya Chandrasekaran. (2026, February 13). Bulimia Statistics. Gitnux. https://gitnux.org/bulimia-statistics
MLA
Priya Chandrasekaran. "Bulimia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/bulimia-statistics.
Chicago
Priya Chandrasekaran. 2026. "Bulimia Statistics." Gitnux. https://gitnux.org/bulimia-statistics.
Sources & references
48 datasets cited across this report · attribution is report-level
+38 additional datasets cited (not shown individually)